A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
Pulmonary arterial hypertension (PAH) - a complex and progressive disease that carries significant morbidity and mortality despite optimal medical treatment. Combination therapy for PAH can be more effective than monotherapy. The present randomized trial compared the safety and efficacy of sildenafi...
Main Authors: | Shaadab Mohammed, Rajesh Vijayvergiya, Samir Malhotra, Manoj Kumar Rohit |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Indian Heart Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0019483221001516 |
Similar Items
-
Ambrisentan-induced severe asymptomatic thrombocytopenia
by: Dana Kigitovica, et al.
Published: (2020-10-01) -
Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis
by: Mengtao Li, et al.
Published: (2020-07-01) -
Extractive Spectrophotometric Determination of Ambrisentan
by: Chandra Bala Sekaran, et al.
Published: (2013-02-01) -
A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
by: Annemarie Schorpion, et al.
Published: (2018-05-01) -
Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
by: Xinmei Li, et al.
Published: (2020-04-01)